ArticlePloS one2023
Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS).
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 20 citations in OpenAlex.
- Dual-targeting oral nanoparticle mucosal vaccine against brucella infection: co-targeting M cells and dendritic cells.Journal of nanobiotechnology · 2026Article
- Immunoinformatics-guided design of a multi-epitope vaccine targeting WISP1 for gastric cancer.BMC biotechnology · 2026Article
- Integrative 16S rRNA characterization, pan-genome, and immunoinformatics approaches for the design of a multi-epitope vaccine against Bacillus cereus, a foodborne pathogen.World journal of microbiology & biotechnology · 2026Article
- ComparativeVeterinary world · 2026Article
- Brucellosis vaccine development: immunological mechanisms, animal models, and future directions.Archives of microbiology · 2026Review
- Immunoinformatics-based design and evaluation of a multi-epitope vaccine against Vibrio fluvialis.Scientific reports · 2026Article
- Article
- Immunoinformatics-driven design of a multi-epitope vaccine againstFrontiers in immunology · 2026Article
- An integrated subtractive genomics and immunoinformatics approach for designing a universal multi-epitope vaccine againstFrontiers in bioinformatics · 2026Article
- Integrating biocomputational techniques for vaccine development for glioblastoma multiforme: a possible way of enhancing precision.Frontiers in immunology · 2026Review
- A Highly Immunogenic and Cross-Reactive Multi-Epitope Vaccine Candidate Against Duck Hepatitis A Virus: Immunoinformatics Design and Preliminary Experimental Validation.International journal of molecular sciences · 2025Article
- Reverse vaccinology-driven construction and bioinformatics validation of a multi-epitope vaccine against Brucella spp.Scientific reports · 2025Article
- Application of Brucella type IV secretion proteins VirB1, VirB5, and VirB6 in the serological diagnosis of brucellosis.Scientific reports · 2025Article
- Design of a multi-Epitope mRNA vaccine against Brucella type IV secretion system using reverse vaccinology and immunogenicity approaches.Scientific reports · 2025Article
- Harnessing immunopeptidomics for next-generation vaccines against intracellular bacterial pathogens.Molecular biology reports · 2025Review
- FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection AgainstVaccines · 2025Article
- Computational design of a glycosylated multi-epitope vaccine against HAsV-1 and HAsV-2 astrovirus for acute gastroenteritis.Scientific reports · 2025Article
- Design of a multi-epitope recombinant BCG vaccine targeting Brucella OMP31, LptE and VirB2 in immunoinformatics approaches.PloS one · 2025Article
- Comprehensive epidemiological evaluation of ruminant brucellosis and associated risk factors in some Egyptian Governorates.Veterinary world · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucellosis is a common zoonosis, which is caused by Brucella infection, and Brucella often infects livestock, leading to abortion and infertility. At present, human brucellosis remains one of the major public health problems in China. According to previous research, most areas in northwest China, including Xinjiang, Tibet, and other regions, are severely affected by Brucella. Although there are vaccines against animal Brucellosis, the effect is often poor. In addition, there is no corresponding vaccine for human Brucellosis infection. Therefore, a new strategy for early prevention and treatment of Brucella is needed. A multi-epitope vaccine should be developed. In this study, we identified the antigenic epitopes of the Brucella type IV secretion system VirB8 and Virb10 using an immunoinformatics approach, and screened out 2 cytotoxic T lymphocyte (CTL) epitopes, 9 helper T lymphocyte (HTL) epitopes, 6 linear B cell epitopes, and 6 conformational B cell epitopes. These advantageous epitopes are spliced together through different linkers to construct a multi-epitope vaccine. The silico tests showed that the multi-epitope vaccine was non-allergenic and had a strong interaction with TLR4 molecular docking. In immune simulation results, the vaccine construct may be useful in helping brucellosis patients to initiate cellular and humoral immunity. Overall, our findings indicated that the multi-epitope vaccine construct has a high-quality structure and suitable characteristics, which may provide a theoretical basis for the development of a Brucella vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.